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Abstract
Background Chemotherapy with bevacizumab alters the
angiogenic environment, and therefore, the growth and
spread of metastases. We present a patient with metastatic
lung adenocarcinoma to the eye with findings suggestive of
retinal vascular co-option.
Methods Case report.
Results A 57-year-old male, receiving systemic bevacizumab
for metastatic lung adenocarcinoma, presented with vitreous
opacities and clumped deposits adherent to the retinal vessels.
No choroidal metastases were present. Diagnostic vitrectomy
yielded cellular evidence of adenocarcinoma, with thyroid
transcription factor-1 staining confirming a lung primary.
Conclusion The perivascular growth of small foci of
metastatic vitreous cells suggests vascular co-option from
the native retinal circulation. Similar modification of
metastatic disease by bevacizumab has been observed in
animal models and selected human cases.
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Introduction
Ocular metastases most commonly present as mass lesions
in the choroid. Retinal metastases and diffuse metastases to
the vitreous have been previously reported in cutaneous
melanoma, and breast and lung adenocarcinoma without
any recognizable angiocentric pattern. We present a patient
with retinal and vitreous metastases from lung adenocarci-
noma whose ocular findings suggest that bevacizumab
treatment resulted in distinctive perivascular growth by
fostering vascular co-option of the retinal vasculature by
metastatic tumor cells.
Case report
We examined a 57-year-old male who presented to the
Bascom Palmer Eye Institute in Oct 2009 with a 6-month
history of floaters in his left eye (OS). He had reported
flashes in the OS 3 months prior and had undergone laser
retinopexy without resolution of symptoms and was now
diagnosed as uveitis. Past medical history was significant
for stage IV non-small cell carcinoma of the lung diagnosed
in Aug 2005 and treated with left pneumonectomy. Within
1 year, brain metastases developed and were treated with
whole brain irradiation, 6-thioguanine, temozolomide, and
stereotactic radiosurgical treatment of some larger masses.
In June 2009, recurrent brain metastases were detected.
Cerebrospinal fluid was negative for malignant cells.
Chemotherapy was resumed. Erlotinib was stopped
2 months prior to presentation, and a 6-week prior MRI
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of the brain showed no evidence of tumor. Treatment with
bevacizumab, capecitabine, and camptosar was ongoing.
He had an implantable venous access device in the right
subclavian vein present for 4 years. The skin over the
device was intact and uninflamed. He was afebrile.
Vision was 20/15 in the right eye (OD) and 20/40 OS.
Pupil exam was normal with a 10% subjective reduction in
light brightness OS. There was mild conjunctival injection in
the OS more than in the OD. He had 1+ anterior chamber
cell OS and no cell OD. There were no posterior synechiae.
Examination of the vitreous and retina OD was entirely
normal. In the OS, there were 2+ vitreous cells, with
clumping (Fig. 1). The cells appeared to ramify on the
surface of the retina with well-defined cellular clumps along
the retinal arteries and veins (Fig. 2). Optical coherence
tomography confirmed a preretinal location (Fig. 2).
Fungal endophthalmitis was considered. A diagnostic
pars plana vitrectomy was performed with intravitreal
injection of 5 μg amphotericin. The vitreous specimen
was sent for histopathology and culture. No organisms were
identified on gram stain. Corynebacterum grew from a
single medium used to culture the vitreous and was
interpreted as a contaminant. Blood and urine cultures were
negative. Millipore preparations of the vitreous specimen
revealed cellular evidence of adenocarcinoma (Fig. 3).
Immunocytochemistry was positive for TTF-1(thyroid
transcription factor-1) indicating a lung primary (Fig. 3).
The patient was referred to his oncologist for further
evaluation and treatment. Temozolomide was added. He
relocated to Maryland. In March 2010, multiple lymph
nodes showed metastatic disease on PET scan, and he was
switched to single agent chemotherapy with gemcitabine.
Vision was 20/70. Some cellular clumps had resolved, and
there were other new ones, including a large peripapillary
lesion (Fig. 4), which remained stable in size over the next
2 months. The right eye remained clinically uninvolved.
Discussion
Lung cancer is the most common origin of ocular
metastases. Malignant cells can metastasize via the systemic
circulation to the high-flow posterior ciliary circulation and
seed the choroid. Retinal metastases can shed into the
vitreous, or the vitreous can be seeded via the highly vascular
ciliary processes of the ciliary body. In cases of central
nervous system malignancy, it is hypothesized that cells may
gain access to the vitreous via the optic nerve. A Medline
search revealed two prior reports of lung cancer metastasizing
to the vitreous that were confirmed by cytologic examination
and cytokeratin staining. [1, 2] Specific TTF-1 immunocy-
Fig. 1 Slit-lamp biomicroscopy OS demonstrating vitreous cell in
retroillumination behind the lens. The inset shows a large cluster of
cells in the anterior vitreous
Fig. 2 Fundus photo OS demonstrating a reticular pattern of vitreous
cellular clumping associated with the retinal vasculature, both arteriole
(white arrow) and venous (black arrow); Upper Inset: OCT OS
demonstrating preretinal vitreous cellular clumping
Fig. 3 H&E stain of vitreous specimen showing atypical epithelial
cells with large and prominent nuclei arranged in small clumps
(×100); Inset: TTF-1 stain of vitreous cells (×40)
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tochemical staining [3] provides an additional tool for
diagnosis of vitreous metastasis from a lung primary.
Preoperative OCT examination confirmed preretinal
localization of the cellular deposits. The striking finding at
surgery was the adherence of individual cellular clumps to
the retinal surface often lining up along the retinal arteries
and veins. Settling of cells into areas of tight vitreous
insertion around the optic nerve or along the large retinal
vessels was unlikely, since the deposits did not change after
inducing a posterior vitreous detachment. The deposits
could be individually aspirated from the retinal surface and
did not form a sheet as would occur if the cells were
growing along the posterior hyaloid.
We propose that the retinal adherence and the predilec-
tion for growth along the retinal vessels represent vascular
co-option by tumor cells in an anti-angiogenic milieu
created by systemic bevacizumab. A solid tumor will not
generally exceed a diameter of 0.4–1.0 mm without first
establishing its own vasculature, [4] which increases
proportionate to tumor size. Use of vascular endothelial
growth factor (VEGF) inhibitors, such as bevacizumab,
thus arrest tumor growth. For comparison, the width of the
optic nerve is approximately 1.5 mm and the width of a
large retinal vein about 0.150 μm. The large optic nerve
deposit seen in March 2010 was roughly 1.0 mm in greatest
dimension (Fig. 3), which may have grown to this extent
only because of co-option of vascular supply from the
oxygen-rich vessels on the nerve face; it may have been
unable to increase further in size without angiogenesis.
Survival of tumor cells by vascular co-option in an anti-
VEGF environment has been demonstrated in animal studies
[5]. In a study by Rubenstein et al. [5], G55 human
glioblastoma cells were inoculated into the basal ganglia of
athymic rats which were then treated with intraperitoneal
anti-VEGF antibody. There was a statistically significant
increase in survival in the anti-VEGF treated animals
compared to untreated controls. Tumors in the untreated
animals grew as well-circumscribed, focal lesions, whereas
tumors in the anti-VEGF treated animals had an infiltrative
and invasive pattern of growth. Ninety per cent of these
small (10 μm) “satellites” were located along a blood vessel,
which was attributed to vascular co-option in an anti-
angiogenic environment. TUNEL staining indicated higher
apoptosis indices in tumor cells remote from blood vessels
compared to tumor cells co-opting the native circulation.
In humans, vascular co-option is also likely to exist. Two
patients with non-small cell lung carcinoma on systemic
bevacizumab developed atypical leptomeningeal carcino-
matosis identified by both neuroradiological imaging and
histopathology [6]. Both cases demonstrated nodular micro-
metastases centered on small blood vessels suggesting co-
option of the normal vasculature.
Fig. 4 Fundus photo, red-free
photo, and fluorescein angio-
gram 5 months post-vitrectomy
OS demonstrating a new large
clump of tumor cells at the optic
nerve head and new cellular
clumps along the retinal arteries
and veins. There is both late
arterial and venous leakage, as
well as macular and optic nerve
leakage
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Conclusion
In summary, we have identified a 57-year-old male on
systemic bevacizumab with vitreous metastasis of TTF-1
positive metastatic non-small cell lung adenocarcinoma
with tumor cell clumping along the retinal vasculature.
We believe that this distribution of cells demonstrates
retinal vascular co-option in an anti-angiogenic environ-
ment similar to that shown in previous animal and
human studies.
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